| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| A H Lichtman, J Peart, J L Poklis, D T Bridgen, R K Razdan, D M Wilson, A Poklis, Y Meng, P R Byron, B R Marti. Pharmacological evaluation of aerosolized cannabinoids in mice. European journal of pharmacology. vol 399. issue 2-3. 2000-09-22. PMID:10884513. |
the goals of the present study were to: (1) develop and characterize the physical properties of an aerosolized form of delta(9)-tetrahydrocannabinol (delta(9)-thc), the major psychoactive constituent present in marijuana; and (2) assess the pharmacological effects of cannabinoid inhalation in mice. |
2000-09-22 |
2023-08-12 |
mouse |
| S E Strau. Immunoactive cannabinoids: therapeutic prospects for marijuana constituents. Proceedings of the National Academy of Sciences of the United States of America. vol 97. issue 17. 2000-09-19. PMID:10931962. |
immunoactive cannabinoids: therapeutic prospects for marijuana constituents. |
2000-09-19 |
2023-08-12 |
Not clear |
| F Nava, G Carta, A M Battasi, G L Gess. D(2) dopamine receptors enable delta(9)-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration. British journal of pharmacology. vol 130. issue 6. 2000-09-13. PMID:10903956. |
our findings suggest that impairment of working memory and inhibition of hippocampal extracellular acetylcholine concentration are mediated by the concomitant activation of d(2) dopamine and cb(1) cannabinoid receptors, and that d(2) dopamine receptor antagonists may be useful in the treatment of the cognitive deficits induced by marijuana. |
2000-09-13 |
2023-08-12 |
rat |
| A A Izzo, N Mascolo, F Capass. Marijuana in the new millennium: perspectives for cannabinoid research. Trends in pharmacological sciences. vol 21. issue 8. 2000-09-01. PMID:10979863. |
marijuana in the new millennium: perspectives for cannabinoid research. |
2000-09-01 |
2023-08-12 |
Not clear |
| E A Vot. Cannabis is not equivalent to cannabinoids. Anesthesia and analgesia. vol 91. issue 2. 2000-08-15. PMID:10910881. |
cannabis is not equivalent to cannabinoids. |
2000-08-15 |
2023-08-12 |
Not clear |
| C J Hillar. Endocannabinoids and vascular function. The Journal of pharmacology and experimental therapeutics. vol 294. issue 1. 2000-07-24. PMID:10871291. |
the active constituents of marijuana, the cannabinoids, exert effects via a g protein-coupled receptor, cb(1). |
2000-07-24 |
2023-08-12 |
human |
| T W Klein, C A Newton, N Nakachi, H Friedma. Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. Journal of immunology (Baltimore, Md. : 1950). vol 164. issue 12. 2000-07-20. PMID:10843702. |
the marijuana cannabinoid, delta 9-tetrahydrocannabinol (thc), suppresses immunity to legionella pneumophila and development of th1 activity and cell-mediated immunity. |
2000-07-20 |
2023-08-12 |
mouse |
| D Piomelli, A Giuffrida, A Calignano, F Rodríguez de Fonsec. The endocannabinoid system as a target for therapeutic drugs. Trends in pharmacological sciences. vol 21. issue 6. 2000-07-18. PMID:10838609. |
cannabinoid receptors, the molecular targets of the cannabis constituent delta9-tetrahydrocannabinol, are present throughout the body and are normally bound by a family of endogenous lipids - the endocannabinoids. |
2000-07-18 |
2023-08-12 |
Not clear |
| G Kunos, Z Járai, K Varga, J Liu, L Wang, J A Wagne. Cardiovascular effects of endocannabinoids--the plot thickens. Prostaglandins & other lipid mediators. vol 61. issue 1-2. 2000-07-13. PMID:10785543. |
cannabinoids, the bioactive ingredients of the marijuana plant, are best known for their psychoactive properties, but they also influence other physiological processes, such as cardiovascular variables. |
2000-07-13 |
2023-08-12 |
Not clear |
| A J Hampson, M Grimaldi, M Lolic, D Wink, R Rosenthal, J Axelro. Neuroprotective antioxidants from marijuana. Annals of the New York Academy of Sciences. vol 899. 2000-07-13. PMID:10863546. |
cannabidiol and other cannabinoids were examined as neuroprotectants in rat cortical neuron cultures exposed to toxic levels of the neurotransmitter, glutamate. |
2000-07-13 |
2023-08-12 |
rat |
| A J Hampson, M Grimaldi, M Lolic, D Wink, R Rosenthal, J Axelro. Neuroprotective antioxidants from marijuana. Annals of the New York Academy of Sciences. vol 899. 2000-07-13. PMID:10863546. |
using cyclic voltametry and a fenton reaction based system, it was demonstrated that cannabidiol, thc and other cannabinoids are potent antioxidants. |
2000-07-13 |
2023-08-12 |
rat |
| A J Hampson, M Grimaldi, M Lolic, D Wink, R Rosenthal, J Axelro. Neuroprotective antioxidants from marijuana. Annals of the New York Academy of Sciences. vol 899. 2000-07-13. PMID:10863546. |
as evidence that cannabinoids can act as an antioxidants in neuronal cultures, cannabidiol was demonstrated to reduce hydroperoxide toxicity in neurons. |
2000-07-13 |
2023-08-12 |
rat |
| S J Watson, J A Benson, J E Jo. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Archives of general psychiatry. vol 57. issue 6. 2000-06-07. PMID:10839332. |
it called for heavier investment in research on the biology of cannabinoid systems, careful clinical studies of cannabinoids in clinical syndromes, analysis of cannabinoids' psychological effects on symptoms, and evaluations of the health consequences of heavy marijuana use; recommends against the use of smoked marijuana in medicine and for the development of a medical cannabinoid inhaler; and recommends that compassionate use of marijuana be considered under carefully reviewed protocols. |
2000-06-07 |
2023-08-12 |
Not clear |
| F Chaperon, M H Thiébo. Behavioral effects of cannabinoid agents in animals. Critical reviews in neurobiology. vol 13. issue 3. 2000-06-02. PMID:10803637. |
the identification of delta9-tetrahydrocannabinol (delta9-thc) as the major active component of marijuana (cannabis sativa), the recent emergence of potent synthetic ligands and the identification of anandamide and sn-2 arachidonylglycerol as putative endogenous ligands for cannabinoid receptors in the brain, have contributed to advancing cannabinoid pharmacology and approaching the neurobiological mechanisms involved in physiological and behavioral effects of cannabinoids. |
2000-06-02 |
2023-08-12 |
Not clear |
| J Molnár, D Szabó, R Pusztai, I Mucsi, L Berek, I Ocsovszki, E Kawata, Y Shoyam. Membrane associated antitumor effects of crocine-, ginsenoside- and cannabinoid derivates. Anticancer research. vol 20. issue 2A. 2000-06-01. PMID:10810367. |
some cannabinoid derivatives such as cannabinol, cannabispirol and cannabidiol increased drug accumulation, while cannabidiolic acid, delta-9-thc and tetrahydro-cannabidiolic acid reduced drug accumulation of the human mdr1-gene transfected mouse lymphoma cells. |
2000-06-01 |
2023-08-12 |
mouse |
| A F Hoffman, C R Lupic. Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 20. issue 7. 2000-05-16. PMID:10729327. |
the localization of cannabinoid (cb) receptors to gabaergic interneurons in the hippocampus indicates that cbs may modulate gabaergic function and thereby mediate some of the disruptive effects of marijuana on spatial memory and sensory processing. |
2000-05-16 |
2023-08-12 |
rat |
| K Soderstrom, F Johnso. CB1 cannabinoid receptor expression in brain regions associated with zebra finch song control. Brain research. vol 857. issue 1-2. 2000-05-04. PMID:10700562. |
cannabinoids have been used for millennia through various preparations of cannabis sativa. |
2000-05-04 |
2023-08-12 |
Not clear |
| A Holdcrof. Adverse effects of cannabis and cannabinoids. British journal of anaesthesia. vol 84. issue 3. 2000-05-04. PMID:10793614. |
adverse effects of cannabis and cannabinoids. |
2000-05-04 |
2023-08-12 |
Not clear |
| D Baker, G Pryce, J L Croxford, P Brown, R G Pertwee, J W Huffman, L Laywar. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. vol 404. issue 6773. 2000-04-03. PMID:10716447. |
this provides a rationale for patients' indications of the therapeutic potential of cannabis in the control of the symptoms of multiple sclerosis, and provides a means of evaluating more selective cannabinoids in the future. |
2000-04-03 |
2023-08-12 |
mouse |
| F Rakhshan, T A Day, R D Blakely, E L Barke. Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. The Journal of pharmacology and experimental therapeutics. vol 292. issue 3. 2000-03-17. PMID:10688610. |
anandamide (n-arachidonylethanolamide) is an endogenous cannabinoid that mimics the pharmacologic effects of delta(9)-tetrahydrocannabinol, the major bioactive substance in marijuana. |
2000-03-17 |
2023-08-12 |
Not clear |